NEJM on anti-CD19 CAR-T cell therapy in B cell lymphoma - 38 pts w/ refractory NHL (24 lg B-cell, 1414 follicular lymphoma) Rx w/ CTL019. 10-yr survival = 32% w/ large B-cell & 47w/ follicular lymphoma; Persistent neutropenia 5%, & 2nd primary cancer seen in 21%. B-cell aplasia https://t.co/CPKvunGZxl